StreetInsider.com News Articles

Form 144 STERIS plc Filed by: Breeden Richard C

Tue, 02 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260602/26591983.html

Form 144 STERIS plc Filed by: Breeden Richard C

Tue, 02 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260602/26591983.html

Form SD STERIS plc

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584257.html

Form SD STERIS plc

Mon, 01 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260601/26584257.html

Form 10-K STERIS plc For: Mar 31

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26574993.html

Form 10-K STERIS plc For: Mar 31

Fri, 29 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260529/26574993.html

Piper Sandler: 'Is now the time to buy STERIS (STE)?'

Thu, 21 May 2026 08:59:15 -0400

Piper Sandler analyst Jason Bednar reiterated an Overweight rating and $270.00 price target on STERIS (NYSE: STE).

The analyst commented: "Is now the time to buy STE? Shares of STE had been in near free fall heading into last week’s FQ4 print and initial FY’27 guide, with concerns manifesting in the lack of any fundamental catalyst materializing in FQ4 and Street estimates that may need to revise lower to account for macro/inflationary pressures (tariffs, oil/freight, input costs/ energy prices). To that end, SI% had been on a slow climb for the past several months after bottoming in mid-25 (albeit still low

Form 3 STERIS plc For: May 05 Filed by: Boulud Pierre

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495775.html

Form 3 STERIS plc For: May 05 Filed by: Boulud Pierre

Thu, 14 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260514/26495775.html

STERIS (STE) PT Lowered to $269 at KeyBanc

Wed, 13 May 2026 08:18:19 -0400

(Updated - May 13, 2026 8:18 AM EDT)

KeyBanc analyst Brett Fishbin lowered the price target on STERIS (NYSE: STE) to $269.00 (from $291.00) while maintaining an Overweight rating.

The analyst commented: "Solid FY27 Guide Outweighing Subdued 4Q for Now; Reiterate OW but reduce PT to $269 given lower peer multiples; 4Q results were below expectations, but we were mostly encouraged by the initial FY27 outlook and view shares as attractive at current levels. More specifically: 1) FY27 organic growth guidance of 6-7% was not a surprise, and consistent with the starting point from recent years; 2) initial FY27 EPS guidance was

STERIS (STE) PT Lowered to $269 at KeyBanc

Wed, 13 May 2026 08:18:19 -0400

(Updated - May 13, 2026 8:18 AM EDT)

KeyBanc analyst Brett Fishbin lowered the price target on STERIS (NYSE: STE) to $269.00 (from $291.00) while maintaining an Overweight rating.

Form SCHEDULE 13G STERIS plc Filed by: STATE STREET CORP

Tue, 12 May 2026 12:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26475978.html

Form SCHEDULE 13G STERIS plc Filed by: STATE STREET CORP

Tue, 12 May 2026 12:04:00 -0400

si-local-file:///var/storage/secattach/20260512/26475978.html

Steris (STE) Misses Q1 EPS by 2c ; Offers Guidance

Tue, 12 May 2026 02:10:29 -0400

Steris (NYSE: STE) reported Q1 EPS of $2.83, $0.02 worse than the analyst estimate of $2.85. Revenue for the quarter came in at $1.6 billion versus the consensus estimate of $1.59 billion.

GUIDANCE:

Steris sees FY2026 EPS of $11.10-$11.30, versus the consensus of $10.20.

For earnings history and earnings-related data on Steris (STE) click here.

Steris (STE) Misses Q1 EPS by 2c ; Offers Guidance

Tue, 12 May 2026 02:10:29 -0400

Steris (NYSE: STE) reported Q1 EPS of $2.83, $0.02 worse than the analyst estimate of $2.85. Revenue for the quarter came in at $1.6 billion versus the consensus estimate of $1.59 billion.

GUIDANCE:

Steris sees FY2026 EPS of $11.10-$11.30, versus the consensus of $10.20.

For earnings history and earnings-related data on Steris (STE) click here.

Form 8-K STERIS plc For: May 11

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469845.html

Form 8-K STERIS plc For: May 11

Mon, 11 May 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260511/26469845.html

STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year

Mon, 11 May 2026 16:30:00 -0400

Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7%
Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share increased to $10.17
Board approves new $1 billion share repurchase program

DUBLIN, IRELAND, May 11, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 fourth quarter and full year ended March 31, 2026. Total revenue from continuing operations for the fourth quarter of fiscal 2026 increased 7%

STERIS Announces Financial Results for Fiscal 2026 Fourth Quarter and Full Year

Mon, 11 May 2026 16:30:00 -0400

Full year fiscal 2026 revenue from continuing operations increased 9%; constant currency organic revenue growth was 7%
Full year fiscal 2026 as reported diluted EPS from continuing operations increased to $7.93; adjusted EPS per diluted share increased to $10.17
Board approves new $1 billion share repurchase program

Form 8-K STERIS plc For: May 01

Thu, 07 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260507/26454432.html

Form 8-K STERIS plc For: May 01

Thu, 07 May 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260507/26454432.html

STERIS names bioMérieux CEO Pierre Boulud to board

Thu, 07 May 2026 16:30:18 -0400

STERIS plc (NYSE: STE) appointed Pierre Boulud to its board of directors, effective May 5, according to a company statement.

Boulud serves as CEO of bioMérieux, a diagnostics company, a position he has held since 2023. He joined bioMérieux in 2016 as corporate vice president for the Asia Pacific region and was promoted to chief operating officer in 2020.

Before joining bioMérieux, Boulud worked for 14 years at Ipsen, a biotechnology company, where he served as executive vice president of specialty care commercial operations. He previously worked as a strategic consultant at Boston Consulting Group.

"His leadership experience, global perspective, strategic acumen, and

STERIS Appoints Pierre Boulud to Board of Directors

Thu, 07 May 2026 16:30:00 -0400

DUBLIN, IRELAND, May 07, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that, effective May 5, 2026, Pierre Boulud has been appointed to the Board of Directors.

“We are pleased to welcome Pierre to our Board,” said Mohsen Sohi, Chairman of STERIS. “His leadership experience, global perspective, strategic acumen, and operational expertise make him an excellent addition to the Board.”

Boulud is CEO of bioMérieux, a world leader in the field of in vitro diagnostics, a role he has held since 2023. Boulud joined bioMérieux in 2016 as Corporate

STERIS Appoints Pierre Boulud to Board of Directors

Thu, 07 May 2026 16:30:00 -0400

Boulud is CEO of bioMérieux, a world leader in the field of in vitro diagnostics, a role he has held since 2023. Boulud joined bioMérieux in 2016 as Corporate

STERIS Announces Dividend of $0.63 per share

Tue, 05 May 2026 16:30:00 -0400

DUBLIN, IRELAND, May 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on June 26, 2026, to shareholders of record at the close of business on June 8, 2026.

Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com.

STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER